By Brad Sorensen, CFA NASDAQ: LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ: LGVN) is a clinical-stage biotechnology company that has positioned itself in the regenerative medicine space ...

The US Food and Drug Administration (FDA) has approved remestemcel-L (Ryoncil, Mesoblast Ltd), an allogeneic bone marrow‒derived mesenchymal stromal cell (MSC) therapy for steroid-refractory acute ...

The "Mesenchymal Stem Cells / Medicinal Signaling Cells (MSCs) - Advances & Applications, 2025" report has been added to ResearchAndMarkets.com's offering. MSCs are multipotent cells that have been ...

Cellular therapy Lomecel-B™ has been granted an International Non-proprietary Name (INN) of “laromestrocel” on the INN List issued by the World Health Organization (WHO) Lomecel-B™ is a proprietary, ...